Harmonizing outcomes with revascularization and stents horizons trial
Download
1 / 3

Harmonizing Outcomes with RevascularIZatiON and Stents HORIZONS Trial - PowerPoint PPT Presentation


  • 260 Views
  • Uploaded on

HORIZONS Trial. Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial. HORIZONS Trial: Study Design. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Harmonizing Outcomes with RevascularIZatiON and Stents HORIZONS Trial' - odell


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Harmonizing outcomes with revascularization and stents horizons trial l.jpg

HORIZONS Trial

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial


Horizons trial study design l.jpg
HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Bivalirudin + Bail-Out IIb/IIIa Inhibitor

n=1700

UFH + IIb/IIIa Inhibitor

n=1700

Target Vessel Stenting to DES vs BMS Randomized 3:1

  • Hypothesis 1: Bivalirudin compared to UFH + routine IIb/IIIa will reduce the composite rate of death, reinfarction, TVR, stroke, and major bleeding at 30 days

Presented at TCT 2005


Slide3 l.jpg

HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Target Vessel Stenting

Randomized 3:1

TAXUS stent

n=2250

Bare metal Express stent

n=750

  • Hypothesis 2: Use of polymer-based slow-release paclitaxel-eluting TAXUS stent will safely reduce the 1 year rate of ischemia-driven TLR

Presented at TCT 2005


ad